Check the time stamp on this data. Updated AI-Generated Signals for Equifax Inc. (EFX) available here: EFX. Type a few ...
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Equifax (EFX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...
Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on Airbus Group SE (EADSF – Research Report) and Equifax ...
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while ...
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
clinicaltrialsarena on MSN6d
Akero’s cirrhosis treatment shows promise in Phase IIb studyAkero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...
Zacks.com on MSN5d
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback